Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 16;105(9):2250–2261. doi: 10.3324/haematol.2018.205047

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2020 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 5. — Modulation of the expression of miRNA and genes involved in their processing in healthy donor neutrophils by inflammatory components - in vitro effects of TCZ and IFX in RA active neutrophils. (A) Serum and synovial levels of TNF-α and IL-6 (40 HD-serum, 40 RA-serum and 40 RA-SF). a: significant differences vs. HD serum P<0.05; b: significant differences vs. RA serum P<0.05. (B) Expression of miRNA and genes involved in their biogenesis machinery in HD neutrophils treated with TNF-a. (C) Expression of miRNA and genes involved in their biogenesis machinery in HD neutrophils treated with IL-6. (D) Expression of miRNA and genes involved in their processing in RA active neutrophils treated in vitro with TCZ or IFX. (E) Gene expression of putative mRNA targets of the validated miRNA in RA active neutrophils treated in vitro with TCZ or IFX. (F) Protein levels of putative mRNA targets of the validated miRNA in RA active neutrophils treated in vitro with TCZ or IFX. miRNA: microRNA; HD: healthy donor; TCZ: tocilizumab; IFX: infliximab; RA: rheumatoid arthritis; AGO-1: argonaute-1; AGO-2: argonaute-2; XPO-5: exportin-5; VEGFA: vascular endothelial growth factor; TNF-a: tumor necrosis factor-alpha; IL-1β: interleukin-1 beta; IL-8: interleukin-8; IL-6R: interleukin-6 receptor; STAT-3: signal transducer and activator of transcription 3; AKT: protein kinase B; Non-t: non-treated. Data are presented as mean ± standard error of the mean (SEM) of five independent experiments; a: significant differences respective non-treated P<0.05.